Vyome Holdings, Inc (HIND) — SEC Filings
Vyome Holdings, Inc (HIND) — 50 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 32 8-K, 6 10-Q, 5 S-1/A.
View Vyome Holdings, Inc on SEC EDGAR
Overview
Vyome Holdings, Inc (HIND) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 19, 2025: Vyome Holdings, Inc. filed an 8-K on November 19, 2025, reporting on its financial condition and results of operations as of November 18, 2025. The filing indicates the company's principal executive offices are located in Cambridge, MA.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 43 neutral, 4 mixed. The dominant filing sentiment for Vyome Holdings, Inc is neutral.
Filing Type Overview
Vyome Holdings, Inc (HIND) has filed 32 8-K, 6 10-Q, 2 DEF 14A, 1 8-K/A, 2 10-K, 5 S-1/A, 1 S-1, 1 SC 13G/A with the SEC between Apr 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of HIND's 48 recent filings, 4 were flagged as high-risk, 28 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $283,163 |
| Net Income | -$9,198,033 |
| EPS | -$10.00 |
| Debt-to-Equity | N/A |
| Cash Position | $5,707,012 |
| Operating Margin | N/A |
| Total Assets | $7,045,396 |
| Total Debt | $3,126,936 |
Key Executives
- Krishna K. Gupta
- Shiladitya Sengupta
- Stash Pomichter
- Venkat Nelabhotla
- Paul E. Savory
- Dr. Jonathan L. Webb
- Dr. David L. Smith
- Mr. David L. Smith
- Paul F. Hickey
- Dr. Steven J. DeMaio
- Dr. David R. Smith
- Mr. David L. Johnson
Industry Context
Vyome Holdings operates in the highly competitive biopharmaceutical sector, focusing on immuno-inflammatory and rare disease treatments. This industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include the increasing demand for targeted therapies and orphan drugs, alongside a growing emphasis on innovative drug discovery platforms.
Top Tags
sec-filing (7) · material-agreement (6) · corporate-governance (5) · shareholder-vote (4) · equity-sale (4) · filing-update (3) · corporate-event (3) · amendment (3) · 8-K (3) · corporate-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $9,198,033 | Increased from $1,140,904 for the nine months ended September 30, 2024 |
| Transactional and Financing Advisory Fees | $7,705,533 | Increased from $0 for the nine months ended September 30, 2024, due to merger |
| Cash and Cash Equivalents | $5,707,012 | Increased from $101,904 at December 31, 2024 |
| Cash from Financing Activities | $7,890,956 | Generated during the nine months ended September 30, 2025 |
| Revenue | $283,163 | Increased from $195,516 for the nine months ended September 30, 2024 |
| Ownership by former VTI holders | 88% | Percentage of common shares after merger and private placement |
| Ownership by former Reshape shareholders | 12% | Percentage of common shares after merger and private placement |
| Shares Outstanding | 5,644,494 | As of November 13, 2025 |
| Loss per share – basic and diluted | $10.00 | For the nine months ended September 30, 2025 |
| Total Stockholders' Equity | $3,918,460 | As of September 30, 2025, up from a deficit of $(4,391,033) at December 31, 2024 |
| Annual Meeting Date | October 28, 2025 | Date stockholders will vote on proposals |
| Record Date | September 17, 2025 | Date for determining stockholders entitled to vote |
| Holders of Record | 98 | Number of stockholders of record as of the Record Date |
| Class I Director Term End | 2028 | Year Class I directors will serve until |
| Equity Incentive Plan Year | 2025 | Year of the proposed Equity Incentive Plan |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Vyome Holdings, Inc (HIND)?
Vyome Holdings, Inc has 50 recent SEC filings from Apr 2024 to Dec 2025, including 32 8-K, 6 10-Q, 5 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HIND filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 43 neutral, 4 mixed. The dominant sentiment is neutral.
Where can I find Vyome Holdings, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vyome Holdings, Inc (HIND) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vyome Holdings, Inc?
Key financial highlights from Vyome Holdings, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HIND?
The investment thesis for HIND includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vyome Holdings, Inc?
Key executives identified across Vyome Holdings, Inc's filings include Krishna K. Gupta, Shiladitya Sengupta, Stash Pomichter, Venkat Nelabhotla, Paul E. Savory and 7 others.
What are the main risk factors for Vyome Holdings, Inc stock?
Of HIND's 48 assessed filings, 4 were flagged high-risk, 28 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Vyome Holdings, Inc?
Forward guidance and predictions for Vyome Holdings, Inc are extracted from SEC filings as they are enriched.